
1.1K
Downloads
60
Episodes
Zero Fluff. Pure Insight.
Get the latest scientific research without the small talk. We dive deep into new publications to give you clear, information-packed summaries—no filler, no chatter.
Stay tuned. Stay informed.
Zero Fluff. Pure Insight.
Get the latest scientific research without the small talk. We dive deep into new publications to give you clear, information-packed summaries—no filler, no chatter.
Stay tuned. Stay informed.
Episodes
2 hours ago
2 hours ago
8 min
E72 | 9 min | Latest | Publication Link
- Podcast based on: Nardo, G.; Lenoci, D.; Lucchetta, M.; Licitra, L.; De Cecco, L.; Cavalieri, S. Immune Cell Engagers and “Masking Immunotherapy” for Solid Tumors: Focus on Head and Neck Cancers. Cancers 2026, 18, 3401. https://doi.org/10.3390/cancers18203401
Type: Review | Publication date: 21 October 2026 - Summary: Head and neck squamous cell carcinomas (HNSCCs) are difficult to treat with current therapeutic options because of anatomical and biological limits. Immune cell engagers (ICEs) are a new generation of engineered antibodies designed to redirect the patient’s own immune cells toward cancer cells, offering the potential to overcome several mechanisms of immune escape. More recently, innovative approaches such as conditionally activated or “masked” platforms have been designed to preferentially restore immune-engaging activity within the TME. Although preclinical studies support the potential of these approaches to reduce systemic immune activation and on-target, off-tumor toxicity, their degree of tumor selectivity and safety benefit in patients remains to be established. In this review, we summarize the current landscape of ICEs in HNSCC and discuss their biological rationale, available preclinical and clinical evidence, and the main barriers limiting their clinical translation. We also highlight emerging engineering strategies and future directions that may help improve the efficacy and safety of these promising immunotherapeutic platforms.
- Keywords: immune-cell engagers; ICE; T-cell engagers; TCE; gamma-delta TCE; NKCE; phagocytic-engager; HNSCCs; head and neck cancers; masking immunotherapy
License and disclaimer:
Original article © 2026 by the authors. Licensed under the Creative Commons Attribution 4.0 (CC BY 4.0) license (https://creativecommons.org/licenses/by/4.0/). This episode is an AI-generated audio adaptation of the article: the script and the voices are synthetic, changes were made, and the adaptation is not endorsed by the authors, the journal, or the publisher. It may contain errors or omissions, so consult the original publication before relying on any detail. It is for educational purposes only and is not medical advice. The creators accept no liability for any use of this content.
2 hours ago
8 min

No comments yet. Be the first to say something!